Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed

Affiliations

¹ Division of Gastroenterology, University of California San Diego, La Jolla, California; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Leuven, Belgium; Robarts Clinical Trials, Western University, London, Ontario, Canada.
² Division of Gastroenterology, University of California San Diego, La Jolla, California; Robarts Clinical Trials, Western University, London, Ontario, Canada.

Editorial

Niels Vande Casteele et al. Clin Gastroenterol Hepatol. 2014 Nov.

. 2014 Nov;12(11):1894-6.

doi: 10.1016/j.cgh.2014.06.011. Epub 2014 Jun 19.

¹ Division of Gastroenterology, University of California San Diego, La Jolla, California; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Leuven, Belgium; Robarts Clinical Trials, Western University, London, Ontario, Canada.
² Division of Gastroenterology, University of California San Diego, La Jolla, California; Robarts Clinical Trials, Western University, London, Ontario, Canada.

No abstract available

Comment on

Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Osterman MT, et al. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30. Clin Gastroenterol Hepatol. 2014. PMID: 24793028 Free PMC article. Clinical Trial.